<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00122525</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 1265</org_study_id>
    <nct_id>NCT00122525</nct_id>
  </id_info>
  <brief_title>Effect of Male Circumcision on HIV Incidence (ANRS 1265)</brief_title>
  <official_title>Effect of Safe Male Circumcision on Incidence of Infection by HIV, HSV-2 and of Genital Ulceration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Agency for Research on AIDS and Viral Hepatitis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational studies suggest that male circumcision may provide protection against HIV-1
      infection. A randomized, controlled, intervention trial was conducted in a general population
      of South Africa to test this hypothesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized controlled intervention trial. This multi-centre study will take
      place in 3 centers located around Johannesburg, in the areas of Orange Farm, Sebokeng and
      Evaton. The intervention group patients (circumcised at the beginning of the trial) and the
      control group (uncircumcised men) will be followed during 21 months (from M.0 to M. 21).
      Randomization and medicalized circumcision will be performed at M.0 in the intervention group
      and might be optional in the control group at end of study. The medicalized circumcision
      effectiveness will be evaluated on and after M.3 (3 months after medicalized circumcision).
      Incidences (of HIV, HSV-2 infections and genital ulcer disease) will be compared from M.3 to
      M.21 between the intervention group and the control group. An intermediate analysis will take
      place at M. 12.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    following DSMB recommandation.
  </why_stopped>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the protective effect of medicalized male circumcision on HIV infection</measure>
    <time_frame>M3, M12 and M21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the protective effect on infections by the genital herpes agent Herpes simplex virus type 2 (HSV-2)</measure>
    <time_frame>M3, M12 and M21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the protective effect on the incidence of genital ulcer disease</measure>
    <time_frame>M3, M12 and M21</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">3274</enrollment>
  <condition>HIV Infections</condition>
  <condition>Herpes Genitalis</condition>
  <condition>Venereal Diseases</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Male Circumcision</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Uncircumcised men aged 18-24 years

          -  Be in good general condition with normal physical and genital examinations

          -  Consenting to participate in the trial and to sign an informed consent

          -  Consenting to randomization of the medicalized circumcision schedule (performed at the
             beginning of study for the treated group, optional at the end of study for the control
             group)

          -  Consenting to avoid sexual contact (except with condom protection) during the 6 weeks
             following the medicalized circumcision

          -  Consenting to blood tests at M.0, M.3, M.12 and M.21 tested for HIV, HSV-2 and
             syphilis.

        Exclusion Criteria:

          -  Men with AIDS

          -  Men with contraindication for circumcision

          -  Men thinking of moving away from the trial sites within the 21 months following
             inclusion

          -  Men with clinical sexually transmitted diseases (STDs) (those men could be included
             after treatment)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertran Auvert, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Ambroise-Paré (AP-HP); Inserm U687</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adrian Puren</last_name>
    <role>Principal Investigator</role>
    <affiliation>NICD, Johannesburg, South Africa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MC Centre</name>
      <address>
        <city>Orange Farm</city>
        <state>Johannesburg</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr</url>
    <description>Sponsor web page</description>
  </link>
  <reference>
    <citation>Auvert B, Marseille E, Korenromp EL, Lloyd-Smith J, Sitta R, Taljaard D, Pretorius C, Williams B, Kahn JG. Estimating the resources needed and savings anticipated from roll-out of adult male circumcision in Sub-Saharan Africa. PLoS One. 2008 Aug 6;3(8):e2679. doi: 10.1371/journal.pone.0002679.</citation>
    <PMID>18682725</PMID>
  </reference>
  <results_reference>
    <citation>Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005 Nov;2(11):e298. Epub 2005 Oct 25. Erratum in: PLoS Med. 2006 May;3(5):e298.</citation>
    <PMID>16231970</PMID>
  </results_reference>
  <results_reference>
    <citation>Sobngwi-Tambekou J, Taljaard D, Nieuwoudt M, Lissouba P, Puren A, Auvert B. Male circumcision and Neisseria gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis: observations after a randomised controlled trial for HIV prevention. Sex Transm Infect. 2009 Apr;85(2):116-20. doi: 10.1136/sti.2008.032334. Epub 2008 Dec 15.</citation>
    <PMID>19074928</PMID>
  </results_reference>
  <results_reference>
    <citation>Sobngwi-Tambekou J, Taljaard D, Lissouba P, Zarca K, Puren A, Lagarde E, Auvert B. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis. 2009 Apr 1;199(7):958-64. doi: 10.1086/597208.</citation>
    <PMID>19220143</PMID>
  </results_reference>
  <results_reference>
    <citation>Auvert B, Sobngwi-Tambekou J, Cutler E, Nieuwoudt M, Lissouba P, Puren A, Taljaard D. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis. 2009 Jan 1;199(1):14-9. doi: 10.1086/595566.</citation>
    <PMID>19086814</PMID>
  </results_reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2005</study_first_submitted>
  <study_first_submitted_qc>July 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2005</study_first_posted>
  <last_update_submitted>April 29, 2009</last_update_submitted>
  <last_update_submitted_qc>April 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2009</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>Male circumcision</keyword>
  <keyword>Prevention</keyword>
  <keyword>HSV-2</keyword>
  <keyword>Africa</keyword>
  <keyword>Sexual behavior</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Herpes Genitalis</mesh_term>
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

